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Weifeng Huang1, Chunjing Lu2, Yong Wu1, Shou Ouyang3 and Yuanzhong Chen1*Abstract
Background: T-type Ca2+ channels are often aberrantly expressed in different human cancers and participate in the
regulation of cell cycle progression, proliferation and death. Methods: RT-PCR, Q-PCR, western blotting and whole-cell
patch-clamp recording were employed to assess the expression of T-type Ca2+ channels in leukemia cell lines. The
function of T-type Ca2+ channels in leukemia cell growth and the possible mechanism of the effect of T-type Ca2+
channel antagonists on cell proliferation and apoptosis were examined in T-lymphoma cell lines.
Results: We show that leukemia cell lines exhibited reduced cell growth when treated with T-type Ca2+ channel
inhibitors, mibefradil and NNC-55-0396 in a concentration-dependent manner. Mechanistically, these inhibitors played
a dual role on cell viability: (i) blunting proliferation, through a halt in the progression to the G1-S phase; and (ii)
promoting cell apoptosis, partially dependent on the endoplasmic reticulum Ca2+ release. In addition, we observed a
reduced phosphorylation of ERK1/2 in MOLT-4 cells in response to mibefradil and NNC-55-0396 treatment.
Conclusions: These results indicate that mibefradil and NNC-55-0396 regulate proliferation and apoptosis in T-type Ca2+
channel expressing leukemia cell lines and suggest a potential therapeutic target for leukemia.
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Intracellular Ca2+ is a crucial secondary messenger that
regulates many cellular processes, such as cell cycle pro-
gression, proliferation and apoptosis [1–3]. Intracellular
Ca2+ levels are regulated by several mechanisms includ-
ing plasma membrane ion channels (e.g., Voltage-gated
and ligand-gated Ca2+ channels), ion exchangers and
“pumps”, as well as the release from the intracellular Ca2+
stores [3]. Orchestration of cytoplasm Ca2+ as evidenced
by pulses, or oscillations, is crucial for cell cycle progres-
sion and therefore proliferation [4], otherwise, excessive
Ca2+ or loss of control in Ca2+ signaling can lead to cell
death [5]. In normal epithelial cells, free Ca2+ concentra-
tion is essential for cells to enter and accomplish the S
phase and the M phase of the cell cycle. Cancer cells
are able to pass these phases with much lower extra-
cellular Ca2+ levels than normal cells [6], indicating* Correspondence: chenyz@mail.fjmu.edu.cn
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unless otherwise stated.that they developed a more efficient mechanism to fa-
cilitate Ca2+ influx.
Among the routes for Ca2+ influx, T-type Ca2+ channel
expression and relationship to proliferation and apoptosis
have been demonstrated in many cancer types, including
leukemic [7], ovarian [8, 9], glioma [10, 11], breast [12],
esophageal [13], hepatoma [14], melanoma [15], and colon
cancers [16]. Moreover, increased expression of T-type
Ca2+ channels can be detected in tumor samples collected
from patients. In addition, these reports also show that
pharmacological inhibition by small molecule antagonists
or RNAi-mediated downregulation of T-type Ca2+ chan-
nels leads to inhibition of cancer cell proliferation and
inducing cancer cell apoptosis. Therefore, T-type Ca2+
channels pose an attractive potential target for cancer
therapy. T-type Ca2+ channels have unique electrophysio-
logical characteristics: low voltage-activated Ca2+ current,
fast (transient) inactivation, slow deactivation and low uni-
tary conductance [17]. To date, the existence of three
different T-type Ca2+ channel subunits, the α1G (Cav3.1),
α1H (Cav3.2) and α1I (Cav3.3) has been revealed [17]. AtThis is an Open Access article distributed under the terms of the Creative
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a “window current” [18], i.e. a sustained inward Ca2+
current carried by the portion of channels that are not
completely inactivated. Hence, T-type Ca2+ channels are
well suited to regulate Ca2+ oscillations under non-
stimulated or resting membrane conditions. This regula-
tion of Ca2+ homeostasis allows T-type Ca2+ channels to
control cell proliferation and apoptosis, or death. There
are increasing data suggest that the expression of T-type
Ca2+ channels is cell cycle-dependent [19–22].
Mibefradil is a potent inhibitor of T-type Ca2+ currents
with 10 to 20 times higher selectivity for T-type over L-
type Ca2+ channels [23]. NNC-55-0396, is a structural
analog of mibefradil with a higher selectivity for T-type
Ca2+ channels, which exerts no effect against high volt-
age Ca2+ channels at 100 μM, but inhibits T-type Ca2+
channels in HEK293 cells with a potency comparable to
that of mibefradil (IC50 values of 6.8 versus 10.1 μM)
[24]. A growing number of reports showed that mibefra-
dil and NNC-55-0396 could prevent human cancer cell
proliferation and induce cancer cell apoptosis as a result
of its ability to inhibit the function of T-type Ca2+
channels [10–16, 23, 24]. Additionally, mibefradil was
FDA-approved for the treatment of ovarian (2007),
pancreas (2008), and glioblastoma multiforme (2009)
tumors. At present, however, the detailed biological
mechanism (s) underlying the anticancer activity of
these channel antagonists has not been explored.
In this study, we examined the function of T-type Ca2+
channels in leukemic cell lines. We showed that inhibition
of T-type Ca2+ channels with antagonists, mibefradil and
NNC-55-0396, led to a decrease in proliferation, and an
increase in apoptosis of leukemia cells in vitro, which was
preceded by disrupting endoplasmic reticulum (ER) Ca2+
homeostasis. We also demonstrated down-regulating ERK
signaling in MOLT-4 cells following the application of
T-type Ca2+ channel antagonists. Since human normal
blood cells do not express T-type Ca2+ channels, our
results suggest that T-type Ca2+ channel inhibitors may
be useful in the treatment of acute lymphocytic
leukemia (ALL).Materials and methods
Cell culture
Human leukemic cell lines MOLT-4, Jurkat, Ball, HL-
60, NB4, HEL, K-562, and U937 were purchased from
the American Type Culture Collection (ATCC; Rock-
ville, MD, USA) and were cultured in RPMI 1640
medium containing 10 % heat-inactivated fetal bovine
serum (Gibco by Life Technologies, Carlsbad, CA,
USA), 1 % pen/strep (MP Biomedicals, Solon, OH,
USA) and 2 mM L-glutamine at 37 °C in 95 % air/
5 % CO2 with 95 % humidity.Isolation of human peripheral blood mononuclear cells
(PBMCs)
Whole blood (5–10 ml) was collected from healthy
human male and female donors (n = 8 each), according
to The Code of Ethics of the World Medical Association.
Mononuclear cells were isolated with human lymphocyte
separation medium (Tbdscience, Tianjin, China) accord-
ing to manufacturer’s instructions. Briefly, PBMCs were
separated by centrifugation at 900 × g for 30 min at 18–
20 °C over a Ficoll-Paque PLUS gradient. The resulting
PBMC layer was washed twice with nuclease-free 0.9 %
NaCl solution and prepared for RNA isolation.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total cellular RNA was isolated from exponentially
growing cells and human PBMCs using RNAsimple
Total RNA Kit (TIANGEN Biotech, Beijing, China).
Messenger RNA was reverse-transcribed (RT) to cDNA
using oligo(dT)15 primers and GoScript reverse tran-
scriptase (Promega, Madison, WI, USA). The cDNA
product was used as a template for subsequent PCR
amplifications for α1G, α1H, and α1I subunit, using
sequence-specific primers. Primer sequences, product
sizes and PCR conditions are summarized in Table 1.
PCR analysis was repeated at least three times with the
same samples to confirm reproducibility of the results.
Quantitative PCR
Total RNA 1 μg was used to generate cDNA with
GoScript reverse transcriptase as above. A 1-μl aliquot
of each synthesized cDNA was analyzed by Quantitative
Real-Time PCR (CFX96 Real-Time System, Bio-Rad,
Singapore) using SYBR Green PCR Master Mix (Takara,
Dalian, China) according to manufacturer’s protocols
and message level was determined using the △Ct
method. Samples were assayed in triplicate for each gene,
and the mean expression was used during subsequent
analysis. Q-RT-PCR was carried out under the following
reaction conditions: stage 1, 95 °C for 30 s (Rep 1); stage
2, 95 °C for 5 s then 60 °C for 1 min (Reps 40).
Western blot analysis
Western blotting was performed as described previously
[25, 26]. Immunoblots were developed with a goat anti-
rabbit horseradish peroxidase-conjugated secondary
antibody (1:10,000; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) incubated for 1 h at room temperature.
Immunoblots were visualized with the ECL immunode-
tection system (Advansta, Menlo Park, CA, USA). The
following primary antibodies were used: anti-Cav3.1(1:200
dilution, rabbit polyclonal, Alomone Labs, Israel), anti-
Cav3.2 (1:200 dilution, rabbit polyclonal, Alomone Labs)
and anti- Cav3.3 (1:200 dilution, rabbit polyclonal,
Alomone Labs), anti-ERK1/2 and anti-pERK1/2 (1:1000
Table 1 Oligonucleotides used to amplify transcripts of T-type Ca2+ channel α1 subunits and GAPDH
Target Sequence Product size(bp) Temp.
α1G F: 5′-TGCTCTGCTTCTTCGTCTTCTT -3′ 152 60.0 °C
R: 5′-CTCATCCTCGTTCTCTGTCTGGT-3′
α1H F: 5′-TTGGGTTCCGTCGGTTCT-3′ 193 56.5 °C
R: 5′-ATGCCCGTAGCCATCTTCA-3′
α1I F: 5′-ATCGGTTATGCTTGGATTGTCA-3′ 203 54.0 °C
R: 5′-TGCTCCCGTTGCTTGGTCTC-3′
GAPDH F: 5′-AGAAGGCTGGGGCTCATTTG-3′ 258 57.5 °C
R: 5′-AGGGGCCATCCACAGTCTTC-3′
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USA), and anti-GAPDH (1:1000 dilution, rabbit poly-
clonal, Goodhere, Hangzhou, China).
Whole-cell patch-clamp recording
Whole-cell voltage-clamp recordings were performed by
following the procedures as described in our previous
studies [27]. For T-current recordings, the cells were
superfused with bath solution containing (in mmol/L):
10 HEPES, 110 TEA-Cl, 10 CsCl, 20 BaCl2, 10 glucose,
pH 7.4 adjusted with TEA-OH. The resistance of
pipettes ranged 3–5 MΩ when filled with internal solu-
tion containing (in mmol/L): 10 HEPES, 120 CsCl, 1
MgCl2, 10 TEA-Cl, 10 EGTA, 5 Na2ATP, 1.2 Creatine
phosphase, pH 7.2 adjusted with CsOH. Liquid junction
potential was not compensated. Following whole cell
access, the cells were held at- 80 mV with test pulses
ranging from −60 mV to +60 mV with 10 mV increments.
Cell growth assay
To determine cell survival and proliferation, cell growth
was quantified using the CellTiter 96 AQ One Solution
Cell Proliferation Assay Kit (Promega, Madison, WI,
USA). Cells were plated in 96-well culture plates at a
density of 1–2 × 104 cells/well in 100 μL of cell culture
media. Cells were treated with different concentrations
of mibefradil or NNC-55-0396 (Sigma-Aldrich, St. Louis,
MO, USA). After drug exposure, 20 μL of CellTiter 96
AQ One Solution Reagent was added to each well and
allowed to incubate for 2 h at 37 °C. The quantity of
formazan product formed, which is directly proportional
to the number of viable cells, was measured on a Multi-
Mode Microplate Reader (MD SpectraMax M3, CA,
USA) at 490 nm wavelength using a reference filter at
650 nm wavelength. Viability assays were performed at
least three times in independent experiments, using trip-
licate measurements in each.
RNAi against α1G and α1H
The target sequence against human both Cav3.1 and
Cav3.2 T-type Ca
2+ channels was designed according toa previous report [12]. RNAi oligonucleotides (Cav3.1/
3.2, 5′- GCCATCTTCCAGGTCATCACA -3′; negative
control scramble sequence, 5′-TTCTCCGAACGTGT
CACGT-3′) were synthesized by Integrated DNA Tech-
nologies and cloned into the lentiviral small interference
RNA (siRNA) vector GV115 (GeneChem, Shanghai,
China). Transduction of shRNA into the MOLT-4 cells
was achieved by a lentiviral infection method. The positive
transfected cells were sorted using the flow cell sorter
and subjected to the CellTiter 96 AQ One Solution
Cell Proliferation Assay. Q-RT-PCR was used to verify
that shRNA decreased T-type Ca2+ channel genes
expression.Flow cytometer cell cycle analysis
Analysis of cell cycle distribution was determined by pro-
pidium iodide (PI) staining and flow cytometry according
to manufacturer’s instructions (Keygen Biotech, Nanjing,
China). Briefly, following treatment, approximately 1 × 106
cells were fixed in 70 % ethanol for 2 h on ice. The cell
pellets were washed with PBS and incubated with 100 μL
RNase A solution for 30 min at 37 °C. PI (400 μL) was
then added and allowed to incubate for an additional
30 min at 4 °C in dark. DNA content was measured by
exciting PI at 488 nm and measuring the emission at
620 nm, using a flow cytometer (BD Accuri C6, Ann
Arbor, MI, USA). Data analysis was carried out using
FlowJo software. Each experiment is representative of at
least three independent experiments.Apoptosis assay
Apoptosis of ALL cells was detected using an annexin
V apoptosis assay, followed by flow cytometry ana-
lysis. In brief, cells were harvested following treat-
ment, washed in PBS, and subjected to Annexin V/PI
staining according to the manufacturer’s protocol
(Keygen Biotech, Nanjing, China). The percentage of
apoptotic cells was evaluated using flow cytometer
(BD Accuri C6).
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Briefly, cells were loaded with 1 μM Fluo-4/AM (Invitro-
gen) for 60 min at 37 °C in 1640 medium, washed 3
times with PBS and resuspended in 1640 or calcium-free
medium. The loaded cells were measured by flow
cytometry in a FACScan (BD Accuri C6) at an excitation
wavelength of 488 nm and an emission wavelength of
520 nm as described below.
Determination of mitochondrial membrane potential
Mitochondrial membrane potential, ψm, was assessed
with 5, 5′, 6, 6′-tetrachloro-1, 1′, 3, 3′-tetraethylbenzi-
midazolylcarbocyanine iodide fluorescent probe (JC-1)
(Beyotime, Nantong, China). The treated and control
cells were harvested and incubated with JC-1 for 20 min
at 37 °C in the dark. The cells were washed and resus-
pended in 100 μL of cold PBS and then analyzed with
flow cytometer (BD Accuri C6).
Statistical analysis
Plots were produced using Origin 7.0 (Microcal Soft-
ware, Inc., Northampton, MA). Results were compared
using unpaired t-tests (for comparing two groups) or
one factor ANOVA analysis followed, where appropriate,
by Student-Newman-Keuls (for multiple comparisons)
post-test. A p-value of less than 0.05 indicated statisti-
cally significant differences between observed effects.
The results are expressed as mean ± SEM.
Results
The expression of T-type Ca2+ channels in human
leukemia cell lines and PBMCs
We first examined the expression of T-type Ca2+ chan-
nels in human leukemia cell lines (MOLT-4, Jurkat, Ball,
HL-60, NB4, HEL, K-562 and U937) using standard
reverse transcriptase PCR (RT-PCR). As shown in Fig. 1a,
these leukemia cell lines examined expressed mRNA for
the T-type α1-subunit except HEL and U937 cells: either
α1G alone (e.g., Jurkat, Ball, HL-60, and NB4), α1G and
α1I (K-562), or all three T-type α1 subunits (MOLT-4).
We additionally determined the quantitative expression of
these channels by qPCR in human leukemia cell lines and
human PBMCs. As shown in Table 2, except α1H in
MOLT-4 cells showed high level, the expression of T-type
α1 subunits in other cells were very weak or negative,
while human PBMCs didn’t express T-type Ca2+ channels.
We also examined the expression of T-type Ca2+ channels
in MOLT-4 and Jurkat T cells employing western blot
analysis. Both Cav3.1 (very weak) and Cav3.2 subunits
were stained in a size of ~260 kD from the cellular extract
of MOLT-4 cells, whereas only Cav3.2 subunit (very weak)
was detected in Jurkat cells (Fig. 1b).
To evaluate the functional expression of T-type Ca2+
channels in MOLT-4 T cells, whole-cell patch-clamprecordings were performed to record the T-type Ca2+
current. Using Ba2+ as a charge carrier, the current acti-
vated at −30 mV, with peak current at 0 mV, and
displayed rapid activation and inactivation kinetics
(Additional file 1: Figure S1). The amplitude of T-current
in MOLT-4 cells varied between 10 and 20 pA (n = 8), and
the mean T-current density was 0.69 ± 0.15 pA/pF.
Figure 1c shows that a ~15 pA T-type Ca2+ current
was elicited by a depolarizing pulse at 0 mV when
held at −80 mV (control). After perfusion of 2 μM of
NNC-55-0396, the T-type Ca2+ current was inhibited
by ~70 %. In addition, MOLT-4 cells showed a mean
resting potential of −30.5 ± 1.8 mV (n = 12) and membrane
capacitance of 14.5 ± 0.7 pF (n = 15). Treatment of T
lymphocytes with mibefradil, a selective inhibitor
against T-type Ca2+ channels, blocked Ca2+ influx
(Additional file 2: Figure S2). These findings indicate
that T-type Ca2+ channels play a significant role in the Ca2+
influx pathways of human leukemia T cell line.
T-type Ca2+ channels blockers reduced the viability of
human ALL cells
Since T-type Ca2+ channels have been previously shown
to be involved with cell proliferation, we wanted to
examine a putative effect of selective T-type Ca2+ channel
antagonists, mibefradil and NNC-55-0396 on the viability
of ALL cells. As shown in Fig. 2a and b, the cell viability of
both MOLT-4 and Jurkat was suppressed by mibefradil
and NNC-55-0396 in a dose-dependent manner after 48 h
treatment. However, mibefradil and NNC-55-0396 ex-
hibited no effect on the growth of U937 and HEL cells
which did not express T-type Ca2+ channels (Fig. 2c and d),
suggesting that the anti-growth effect of both agents
most likely resulted from blocking T-type Ca2+ channels
of ALL cells.
To further demonstrate that T-type Ca2+ channels are
indeed involved in ALL cell growth, we treated MOLT-4
cells with shRNA targeting to both a1G and a1H (a1G/
H) to knocked down T-type Ca2+ channels. As shown in
Fig. 3a, shRNA-transduced cells had significantly lower
growth rates compared to the scrambled-shRNA infec-
tion and vehicle control group. Together, these results
suggest that the functional T-type Ca2+ channels con-
tribute to the growth of human T cell leukemia lines.
Mibefradil and NNC-55-0396 inhibited ALL cell growth via
cell cycle arrest and inducing cell apoptosis
To address how cell growth was inhibited by mibefradil
and NNC-55-0396, cell cycle was examined. Mibefradil
and NNC-55-0396 not only reduced the proliferation
rate, but also induced apoptosis. After incubation with
mibefradil or NNC-55-0396 for 48 h, the percentage of
MOLT-4 cells in the G0/G1 phase was significantly
enhanced, whereas that in the S phase was markedly
Fig. 1 Expression of T-type Ca2+ channels in human leukemic cell lines. a RT-PCR expression analysis of T-type Ca2+ channel α1-subunits in
human leukemic cell lines. α1G:35 cycles, α1H: 35 cycles, α1I: 37 cycles. b The protein expression levels of T-type Ca2+ channel α1-subunits (Cav3.1
and Cav3.2) in MOLT-4 and Jurkat cells were determined by Western blot analysis. Right panel showed relative protein expression levels of Cav3.1
and Cav3.2 compared to GAPDH. c T-type Ca
2+ currents recorded in a MOLT-4 cell before and after application of 2 μM NNC-55-0396 in 20 mM Ba2+-
containing bathing solution. The holding potential was −80 mV and the test potential was 0 mV. NNC, trace recorded 5 min after 2 μM NNC-55-0396
was perfused into the bath
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of the T-type Ca2+ channel antagonists induced a
remarkable increase in the number of cells at the sub-
G1 phase, a hallmark of cell apoptosis. While in Jurkat
cells, mibefradil and NNC-55-0396 mainly induced cell
apoptosis confirmed by a significant increase in the
percentage of cells at the sub-G1 phase (Fig. 4a and c,
left panel). The discrepancy of both antagonists on cellTable 2 Q-RT-PCR detected T-type Ca2+ channel α1 subunits expres
Target MOLT-4 Jurkat Ball NB4 H
α1G 14.81 ± 0.57 14.37 ± 0.25 15.21 ± 0.27 18.12 ± 0.34 1
α1H 10.69 ± 0.43 12.60 ± 0.39 NA, Ct > 40 NA, Ct > 40 N
α1I 17.55 ± 0.66 NA, Ct > 40 NA, Ct > 40 NA, Ct > 40 Ncycle of MOLT-4 and Jurkat cells may arise from the
different expression level of T-type Ca2+ channels. The
cytotoxicity of both inhibitors was also verified by FACS
analysis of Annexin V-FITC and PI stained cells (Fig. 4d
and e). In addition, cell death following treatment with
both inhibitors was also confirmed by characteristics of
apoptosis, such as cell shrinkage and chromatic agglutin-
ation (data not shown). Together these results indicatesion on human leukemic cell lines and PBMCs (ΔCt)
L60 HEL U937 K562 PBMCs
7.52 ± 0.31 NA, Ct > 40 NA, Ct > 40 NA, Ct > 40 NA, Ct > 40
A, Ct > 40 NA, Ct > 40 NA, Ct > 40 NA, Ct > 40 NA, Ct > 40
A, Ct > 40 NA, Ct > 40 NA, Ct > 40 17.21 ± 0.36 NA, Ct > 40
Fig. 2 Effect of T-type Ca2+ channel blockers, mibefradil and NNC-55-0396 on cell growth. MOLT-4 (a), Jurkat (b), U937 (c) and HEL (d) cells were
cultured in the present of mibefradil or NNC-55-0396 (2–10 μM) for 48 h. All data points represent an average of three to five experiments
(± SEM). *P < 0.05 versus control, **P < 0.01 versus control
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Fig. 3 Effect of shRNA-induced Cav3.1/Cav3.2-gene silencing on MOLT-4 cell growth. a Transduction of shRNA into the MOLT-4 cells was achieved
by a lentiviral infection method according to the manufacturer’s instructions. Cell growth was observed after 48 h growth in normal, shRNA-transduced,
and scrambled-shRNA infection control group. b Q-PCR analysis of the level of Cav3.1/Cav3.2 knockdown. Data are mean ± SEM of three independent
experiments in triplicates. **P < 0.01 versus scrambled-shRNA control group
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viability: (a) blunting proliferation; and (b) promoting
cell apoptosis.
Mibefradil and NNC-55-0396 down-regulated ERK signaling
pathway in MOLT-4 cells
It has been reported that Ca2+ can interact with the MAP
kinase signaling pathway in T lymphocytes [28–30], andMAP kinase signaling pathway plays an important role in
regulating cell cycle progression. Therefore we investi-
gated whether T-type Ca2+ channel antagonists, mibefradil
and NNC-55-0396 could modulate the expression of the
p44/42 MAP kinase in MOLT-4 cells. As shown in Fig. 5b
and c, a persistent decrease of phosphorylated ERK1/2
was detected after treatment with either inhibitor, except
for a transient enhanced phosphorylation of ERK1/2 after
Fig. 4 (See legend on next page.)
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Fig. 4 Effect of T-type Ca2+ channel antagonists, mibefradil (Mib) and NNC-55-0396 (NNC), on the cell cycle distribution and cell apoptosis of
Jurkat and MOLT-4 cells. a-c Each cell was treated with different concentrations (0, 5 or 10 μM) of mibefradil or NNC-55-0396 for 48 h. To acquire
enough cells for cell cycle analysis, Jurkat cells were treated with 8 μM NNC-55-0396. Cell cycle phase was determined using flow cytometry (FACS).
d-e Cells were stained with Annexin V -FITC and propidium iodide (PI) after treatment with 10 μM mibefradil or NNC-55-0396 for 48 h (except Jurkat
cells subjected to NNC-55-0396 for 24 h). Flow cytometry profiles represent annexin V-FITC staining in x-axis and PI in y-axis for the three experimental
conditions. Percentage of each LR and UR area represents Annexin V-positive/PI-negative (early apoptotic) and Annexin V-positive/PI-positive cells (late
apoptotic), respectively. Mibefradil and NNC-55-0396 had a dual effect on cell viability: (a) reducing the proliferation rate; and (b) increasing cell
apoptosis. c and e Histogram bars representing the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 versus control
group. Statistical significances were determined using one factor ANOVA and Student-Newman-Keuls post-test
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mibefradil and NNC-55-0396 induced the decrease of
pERK1/2 in a concentration-dependent manner except
10 μM NNC-55-0396, which induced a robust phos-
phorylation of ERK1/2 (Fig. 5a), in consistent with the
Ca2+ overload after 10 μM NNC-55-0396 treatment
(Additional file 3: Figure S3). These data suggest that
mibefradil and NNC-55-03963 could modulate phosphor-
p44/42 MAP kinase activation via regulating intracellular
Ca2+ level, which may contribute to both inhibitor effects
on cell growth in ALL cells.Fig. 5 T-type Ca2+ channel antagonists, mibefradil and NNC-55-0396 modula
cells were incubated with different concentration of mibefradil or NNC-55-039
NNC-55-0396 for various time-points from 0 to 24 h. Cell lysates were separat
probed with a phosphospecific Ab to detect activated Erk1/2 (top panel). The
Erk1/2 to detect the total amount of kinase loaded in each lane (middle pane
The results are presented as mean ± SEM of three independent experiments.NNC-55-0396 induced endoplasmic reticulum calcium
release
Disruption of intracellular Ca2+ homeostasis is one of
the primary processes in the early development of cell
injury [31–33], and NNC-55-0396 had stronger cytotox-
icity than mibefradil, especially for Jurkat cells. Thus, we
examined the effect of NNC-55-0396 on intracellular
Ca2+ level in Jurkat cells using flow cytometry. After
NNC-55-0396 treatment, a dose-dependent increase in
cytosolic Ca2+ concentration was seen in the absence of
extracelluar Ca2+ (Fig. 6b). Moreover, low concentrationted phospho-p44/42 MAP kinase activation in MOLT-4 cells. a MOLT-4
6 for 48 h. b-c MOLT-4 cells were treated with 10 μΜ Mibefradil or
ed by SDS-PAGE and transferred to PVDF membranes. Membranes were
membrane was stripped and reprobed with an Ab directed against
l). GAPDH was used as a loading control for each lane (bottom panel).
*P < 0.05, **P < 0.01 compared with untreated control cells
Fig. 7 NNC-55-0396 exposure increased intracellular baseline Ca2+
levels via inducing ER calcium release. Jurkat T cells stained with Fluo-4
were preincubated with 1–10 μM NNC-55-0396 in the absence of
extracellular Ca2+. For each sample, after the 10 min pretreatment with
different concentrations of NNC-55-0396 baseline Ca2+ measurements
were taken, cells were then stimulated at the 2 min mark with 1 μM
thapsigargin (TG) to induce the endoplasmic reticulum (ER) Ca2+
release, and the analysis was immediately resumed. The results
depicted are representative of three independent experiments
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Ca2+ levels, while high concentration NNC-55-0396
(>5 μM) diminished or abolished the inhibiting effect of
intracellular baseline Ca2+ levels in the present of extra-
celluar Ca2+ (Fig. 6a). In addition, 10 μM NNC-55-0396
induced sustained Ca2+ overload (Fig. 6a, Green line). In
fact, high concentration mibefradil and NNC-55-0396
also induced intracellular Ca2+ overload in MOLT-4 cells
(Additional file 3: Figure S3).
Because endoplasmic reticulum (ER) is the major Ca2+
store of intracellular Ca2+, and T-type Ca2+ channels
have been suggested to couple Ca2+ influx to ER Ca2+
storage [34], we asked whether NNC-55-0396 would
cause a disruption of Ca2+ homeostasis at the ER, ultim-
ately leading to enhanced apoptosis. We first measured
whether the response of Jurkat cells to thapsigargin (TG,
an agent irreversibly inhibits (sarco) endoplasmic
reticulum Ca2+-ATPase (SERCA) and depletes ER Ca2+
stores) could be altered by NNC-55-0396. As shown in
Fig. 7, TG-driven increase in [Ca2+] i was attenuated
when cells were pretreated with NNC-55-0396. Similar
results were obtained with MOLT-4 cells (data not
shown). These findings suggest that NNC-55-0396
depletes Ca2+ from the ER.
A proximal target of Ca2+ signals arising from the ER
is the mitochondrial network [35]. Several observations
underline the significance of the role of this ER-
mitochondrial Ca2+ flux in stimulating apoptosis [36].
Therefore we decided to address whether NNC-55-
0396-induced ER Ca2+ release had a putative effect on
depolarization of the mitochondrial membrane potential,
resulting in cell apoptosis. To this end, we first measured
the effect of NNC-55-0396 on mitochondrial membraneFig. 6 Effect of T-type Ca2+ channel antagonist, NNC-55-0396 on intracell
were preincubated with 2.5-10 μM NNC-55-0396 in the presence of extracellu
concentrations of NNC-55-0396 baseline Ca2+ measurements were taken, cell
monoclonal antibody (mAb), OKT3 (R&D Systems, Minneapolis, MN, USA) to a
loaded Jurkat cells were treated with 2.5-10 μM NNC-55-0396 and stimulated
independent experimentspotential in Jurkat cells. As shown in Fig. 8b, NNC-55-
0396 induced depolarization of the mitochondrial mem-
brane potential significantly compared to control after
incubation for 2 h (P < 0.05).
To test whether NNC-55-0396 induced depolarization
of the mitochondrial membrane potential arises from ERular Ca2+ levels in Jurkat T cells. a Jurkat cells stained with Fluo-4
lar Ca2+. For each sample, after the 10 min treatment with different
s were then stimulated at the 2 min mark with 10 μg/ml soluble anti-CD3
ctivate Ca2+ influx, and the analysis was immediately resumed. b Fluo-4
in the absence of extracellular Ca2+. Results are representative of 3
Fig. 8 Effects of the mitochondrial uniporter antagonist RU360 and mitochondrial permeability transition pore (mPTP) inhibitor CsA on
NNC-55-0396-induced cell apoptosis and depolarization of the mitochondrial membrane potential in Jurkat cells. a Live cells were examined by 2
parameters: forward scatter/side scatter (FSC/SSC) index of live cells in cell size and granularity by FACScan. Cells were preincubated with mitochondrial
calcium uptake (Ru360, 20 μM) or mitochondrial permeability transition pore (mPTP) inhibitor (cyclosporine A [CsA], 1 μM) for 1 h, then incubated for 6 h
in the presence of 10 μM NNC-55-0396. b Cells were preincubated with mitochondrial calcium uptake (Ru360, 20 μM) or mitochondrial
permeability transition pore (mPTP) inhibitor (CsA, 1 μM) for 1 h, then incubated for 2 h in the presence of 10 μM NNC-55-0396. Then
the mitochondrial membrane potential was determined by FACS. Results are presented as mean ± SEM of four independent experiments.
**p < 0.01 versus control group (−) NNC-55-0396, ## p < 0.01 versus control group (+) NNC-55-0396, *p < 0.05 versus control group
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stasis, Ru360 (20 μM, mitochondrial calcium uptake
inhibitor) or cyclosporine A (CsA, 1 μM, mitochondrial
permeability transition pore (mPTP) inhibitor) was pre-
incubated with Jurkat cells for 1 h before NNC-55-0396treatment. Unexpectedly, neither of the compounds had
significantly protective effect on mitochondrial mem-
brane potential (Fig. 8b). In addition, neither of the com-
pounds had any protective effect on cell viability
(Fig. 8a). Inversely, CsA enhanced the cytotoxicity of
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ition effect of CsA on Calcineurin. In addition, neither
of the compounds had any protective effect on mitochon-
drial membrane potential and cell viability in MOLT-4
cells (Additional file 4: Figure S4). These findings demon-
strate that the effect of NNC-55-0396 on depolarization of
the mitochondrial membrane potential may not directly
depend on ER Ca2+ release.
Discussion
In the present investigation, we have identified the
expression of T-type Ca2+ channels in human leukemic
cell lines. We also demonstrated that T-type Ca2+ chan-
nel antagonists, mibefradil and NNC-55-0396 not only
reduced the proliferation of ALL cells, but also induced
apoptosis. Furthermore, mibefradil and NNC-55-0396
disrupted intracellular calcium homeostasis, partially
from ER Ca2+ release. Mibefradil and NNC-55-0396 mod-
ulated phospho-p44/42 MAP kinase activation in MOLT-
4 T cells. Our study provides a potential that T-type Ca2+
channels may be a potential target for ALL therapy.
Cancer cells have been reported to be relatively
insensitive to reductions in extracellular calcium concen-
tration [37]. Ca2+-dependent signalling is frequently
deregulated in cancer cells and, importantly, voltage-
gated calcium channels (VGCCs) may play a role in
remodelling Ca2+ homeostasis. Abnormal up-regulation
of the gene encoding T-type Ca2+ channel was detected
in various tumour cells [38], suggesting that T-type Ca2+
channels play a role in cancer development.
In the present study, because MOLT-4 cells expressed
high level of T-type Ca2+ channels, they were used for
patch-clamp recording analysis. The patch-clamp
recording results demonstrate that the current in MOLT-4
cells activated at −30 mV, with peak current at 0 mV, in-
consistent with other reports of recording T-current
[11, 13, 39]. The discrepancy may have arisen from dif-
ferent cell lines used in the study. Furthermore,
current-clamp recordings show that the mean resting
potential was −30.5 ± 1.8 mV in MOLT-4 cells. In
addition, the flow cytometric calcium flux assay indi-
cates that cultured T-ALL cells displayed a basal Ca2+
influx which can be reduced by T-type Ca2+ channel
blockers. Together, these results are consistent with the
occurrence of T-type Ca2+ channel window currents,
providing the pattern of Ca2+ signaling required for cell
cycle progression.
Several studies with in vitro systems have demon-
strated that antagonists of T-type Ca2+ channels reduce
cancer cell proliferation and viability [40]. In addition,
inhibition of T-type Ca2+ channels with mibefradil had
been shown to induce apoptosis in breast cancer cells
[41] and glioblastoma cells [10]. This observation sup-
ports the idea that T-type Ca2+ channels function asregulators of survival and/or apoptosis signaling. In this
study, blocking the functional T-type Ca2+ channels
significantly decreased the growth of Jurkat and MOLT-
4 cells, while mibefradil and NNC-55-0396 had no effect
on the growth in U937 and HEL cells, which didn’t
express T-type Ca2+ channels. These results demonstrate
a strong correlation between T- type Ca2+ channels
expression and growth inhibition. Interestingly, we
found that the lower-expression cell line (Jurkat) showed
a larger growth inhibition than the higher-expressing cell
line (MOLT-4), especially for NNC-55-0396 treatment.
The phenomenon may attribute to NNC-55-0396-in-
duced Ca2+ release in Jurkat cells, resulting in a larger
cell death. In addition, the high percentage of sub-G1
phase upon NNC-55-0396-treatment also indicates that
the Jurkat cell death is due to its inherent strong cyto-
toxicity as well as T-type Ca2+ channel blockade. Cell
cycle analysis data demonstrated that mibefradil and
NNC-55-0396 had a dual effect on cell viability: (a)
decreasing proliferation rate; (b) inducing cell apoptosis.
As shown in Fig. 4b and c (right panel), mibefradil and
NNC-55-0396 inhibited MOLT-4 cells proliferation rate
through a halt in the progression to the G1-S phase.
Ca2+ is an essential regulator of the cell cycle and is
indispensable for cell proliferation. For example, the
transition from the G1/S interphase (initiation of DNA
synthesis) and the G2/M interphase (initiation of
mitosis), is dependent upon Ca2+/calmodulin-dependent
kinase II (CaM-kinase II) [42]. In proliferating cells,
these Ca2+ signals are often organized in oscillatory pat-
terns involving entry of external Ca2+ and release of Ca2+
from internal stores. T-type Ca2+ channels are particular
well suited to participate in such oscillations due to their
low voltage activation ranges, transient kinetics of inacti-
vation and “window current”. Indeed, many proliferating
cells exhibit T-type Ca2+ current, including a variety of
tumour cells [38, 40]. As shown in Additional file 2: Figure
S2 and Fig. 6a, blocking T-type Ca2+ channels with
pharmacological blockers reduced intracellular calcium
concentration, confirming the role of these channels in
calcium concentration maintenance.
Mibefradil was originally presented as a T-type Ca2+
channel blocker and has been used in many studies to
establish this putative causal link between T-type Ca2+
channels and cell proliferation. However, mibefradil has
also been reported to inhibit cell proliferation through
an association with cell swelling and the inhibition of
volume-sensitive Cl− channels [43, 44] or several other
ion channels [45–47]. Son et al. reported that NNC-55-
0396 inhibited voltage-dependent K+ channels in rabbit
coronary arterial smooth muscle cells [48]. Thus, the
inhibitory effects on cell proliferation of non-specific T-
type Ca2+ channel blockers should be carefully attributed
to T-type Ca2+ channel blockage.
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long been associated with apoptotic cell death [49]. For
example, a larger and more prolonged Ca2+ changes
(Ca2+ surge or Ca2+ overload) could trigger cell death.
Therefore, the question arises, why blocking T-type Ca2+
calcium channels, which should inhibit calcium influx
from the external environment, paradoxically induces an
extensive apoptotic response in ALL cells? One possible
explanation lies on the fact that cytosolic Ca2+ can be
increased not only through influx from outside, but also
via release of calcium ions from the internal stores. As
shown in Fig. 6b and Fig. 7, NNC-55-0396 could
increase cytosolic Ca2+ level from inducing ER Ca2+
release. In addition, mibefradil at high concentration
(≥10 μM) also induced intracellular Ca2+ overload
(Additional file 3: Figure S3). These results are con-
sistent with a recent report that mibefradil at
supratherapeutic concentrations (≥10 μM) induced Ca2+
release from IP3R-operated Ca2+ stores in rat cardiac
fibroblasts and human platelets in vitro [50]. Furthermore,
the work by Das et al. in melanoma cells demonstrated
that mibefradil and pimozide both induce ER stress
followed by autophagy, culminating in apoptotic cell death
[51]. Valerie et al. reported that targeting T-type Ca2+
channels inhibits mTORC2/Akt pro-survival signaling
pathways and induces apoptosis [10]. It appears that both
the specificity of the inhibitor and the properties of the
model system used may determine the final cellular
response to T-type Ca2+ channel blockage: cell cycle
arrest, apoptosis, autophagy, necrosis, or any combination
of them.
The ER and mitochondria are crucial nodes at which
intracellular Ca2+ fluxes are governed and are the princi-
pal locations for signaling cell fate choices. In addition, a
proximal target of Ca2+ signals arising from the ER is
the mitochondrial network. Thus the potential involve-
ment of mitochondria was also determined. It is known
that exposure of mitochondria to high Ca2+ concentra-
tions results in their swelling and uncoupling. This
phenomenon leads to a loss of maintenance of cellular
ATP levels and finally to cell death by necrosis [52]. In
our study, Ru360, a specific mitochondrial calcium
uptake inhibitor (uniport transporter inhibitor) and
cyclosporine A (mPTP inhibitor) were not associated
with any effect on NNC-55-0396 toxicity, suggesting
that mitochondrial calcium uptake may not be involved
in the toxicity in our model. In addition, ER stress, as a
result of chronic depletion of Ca2+ from the ER, is also a
signal for cell death. The work by Das et al. showed that
T-type channel inhibition or down-regulation results in
the activation of the IRE1 pathway (giving rise to XBP-1 s)
and, possibly, also of the protein kinase RNA-like ER
kinase (PERK) or ATF6 pathways of the UPR (inducing
GADD153) [51]. Thus ER stress may play an importantrole in inducing cell apoptosis in our study. Because Ca2+
has close association with MAPK signaling pathway, we
next investigated whether mibefradil and NNC-55-0396
can modulate MAP kinase activity. MAP kinase signaling
pathway plays an important role in regulating cell cycle
progression, and T-type Ca2+ channel inhibitors blunted
cell proliferation—through a halt in the progression to the
G1-S phase in MOLT-4 cells, so MOLT-4 cells were used
as a model to study ERK signaling pathway. We report
here that both inhibitors down-regulated ERK signaling
pathway in MOLT-4 cells, in agreement with Kotturi
report that inhibition of Ca2+ influx decreased the phos-
phorylation of ERK1/2 [28]. Since ERK1/2 plays an
important role in regulating cell proliferation, the inhib-
ition of ERK1/2 signaling pathway may be associated with
the proliferation inhibition of MOLT-4 cells with mibefra-
dil and NNC-55-0396 treatment.
Conclusions
We have shown both molecular and extensive pharma-
cological evidence for the presence of a T-type Ca2+
channel in leukemia cell lines. Mibefradil and NNC-55-
0396 had a dual role on cell viability: (a) inhibiting cell
proliferation; (b) promoting cell apoptosis. Mechanistic-
ally, both T-type Ca2+ channel inhibitors induced ER Ca2
+ release and disrupted ERK1/2 signaling pathway. Based
on these observations and in vivo results reported
elsewhere, we propose that T-type Ca2+ channel blockers
may be utilized as future therapies for neoplasm express-
ing T-type channels.
Additional files
Additional file 1: Electrophysiological recordings from MOLT-4 T
cells. (A) Traces showing typical recording of the T-type Ca2+ current
(Ba2+ current) triggered from a holding potential of −80 mV to
30 ms-long depolarizing steps at −60 to +30 mV (10 mV increments)
with an interpulse interval of 2 s in 20 mM Ba2+-containing bathing solution.
(B) A plot of the current–voltage relationship for the Ca2+ current recorded as
detailed in (A).
Additional file 2: Effect of T-type Ca2+ channel antagonist,
mibefradil on intracellular Ca2+ levels in Jurkat T cells. Jurkat T cells
stained with Fluo-4 were preincubated with 0.5-10 μM mibefradil in the
presence of extracellular Ca2+. For each sample, after the 10 min treatment
with different concentrations of mibefradil baseline Ca2+ measurements
were taken, cells were then stimulated at the 2 min mark with 10 μg/ml
soluble anti-CD3 monoclonal antibody (mAb), OKT3 to activate Ca2+ influx,
and the analysis was immediately resumed. Results are representative of 3
independent experiments.
Additional file 3: Effect of T-type Ca2+ channel antagonists,
mibefradil and NNC-55-0396 on intracellular Ca2+ levels in
MOLT-4 T cells. Graphs show the effect of high concentration mibefradil
and NNC-55-0396 on the intracellular baseline Ca2+ levels in the presence of
extracellular Ca2+. Results are representative of 3 independent experiments.
Additional file 4: Effects of the mitochondrial uniporter antagonist
RU360 and mitochondrial permeability transition pore (mPTP) inhibitor
CsA on NNC-55-0396-induced cell apoptosis and depolarization of the
mitochondrial membrane potential in MOLT-4 cells. (A) Live cells were
examined by 2 parameters: forward scatter/side scatter (FSC/SSC) index
Huang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:54 Page 14 of 15of live cells in cell size and granularity by FACScan. Cells were
preincubated with mitochondrial calcium uptake (Ru360, 20 μM) or
mitochondrial permeability transition pore (mPTP) inhibitor (cyclosporine
A [CsA], 1 μM) for 1 h, then incubated for 12 h in the presence of 10 μM
NNC-55-0396. (B) Cells were preincubated with mitochondrial calcium
uptake (Ru360, 20 μM) or mitochondrial permeability transition pore (mPTP)
inhibitor (CsA, 1 μM) for 1 h, then incubated for 8 h in the presence of
10 μM NNC-55-0396. Then the mitochondrial membrane potential was
determined by FACS. Results are presented as mean ± SEM of four
independent experiments. **p < 0.01 versus control group (−)
NNC-55-0396, *p < 0.05 versus control group.
Abbreviations
ALL: Acute lymphocytic leukemia; ER: Endoplasmic reticulum;
PBMC: Peripheral blood mononuclear cell; PI: Propidium iodide; PERK:
RNA-like ER kinase; UPR: Unfolded protein response; TG: Thapsigargin;
CsA: Cyclosporine A; VGCC: Voltage-gated calcium channel.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WFH designed the study, performed the experiments, analyzed the data and
wrote the manuscript; CJL performed experiments; SOY provided technical
expertise; YZC and YW provided technical expertise and edited the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
This project was supported by the Chinese National Key Program of Clinical
Science (Hematology), the Fujian Provincial Key Laboratory on Hematology
Program (No. 2009 J1004), Natural Science Funding of Fujian Province (No.
2013D009), the Department of Health of Fujian Province (No. 2014-CXB-48),
the Key Sci-Tech Special Project of Fujian (No. 09ZD001), Scientific Research
Foundation for the Young Scholars of Fujian Province (No. 2010-2-112), and
Project of Xiamen Municipal Science and Technology Commission (No.
3502Z20134044).
Author details
1Fujian Institute of Hematology, Fujian Medical University Union Hospital,
Fuzhou 350004, People’s Republic of China. 2Department of Blood
Transfusion, Maternal and Child Health Hospital of Xiamen, Xiamen 361003,
People’s Republic of China. 3Xiamen Medical Research Institute, Xiamen
361008, People’s Republic of China.
Received: 24 March 2015 Accepted: 8 May 2015
References
1. Clapham DE. Calcium signaling. Cell. 2007;131:1047–58.
2. Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps
in cancer: changes and consequences. J Biol Chem. 2012;287:31666–73.
3. Bergner A, Kellner J, Tufman A, Huber RM. Endoplasmic reticulum
Ca2 + −homeostasis is altered in small and non-small cell lung cancer
cell lines. J Exp Clin Cancer Res. 2009;28:25.
4. Ciapa B, Pesando D, Wilding M, Whitaker M. Cell-cycle calcium transients
driven by cyclic changes in inositol trisphosphate levels. Nature. 1994;368:875–8.
5. Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci.
1987;7:369–79.
6. Boynton AL, Whitfield JF, Isaacs RJ, Tremblay RG. Different extracellular
calcium requirements for proliferation of nonneoplastic, preneoplastic, and
neoplastic mouse cells. Cancer Res. 1977;37:2657–61.
7. Toyota M, Ho C, Ohe-Toyota M, Baylin SB, Issa JP. Inactivation of CACNA1G,
a T-type calcium channel gene, by aberrant methylation of its 5′CpG island
in human tumors. Cancer Res. 1999;59:4535–41.
8. Heo JH, Seo HN, Choe YJ, Kim S, Oh CR, Kim YD, et al. T-type Ca2+ channel
blockers suppress the growth of human cancer cells. Bioorg Med Chem
Lett. 2008;18:3899–901.
9. Li W, Zhang SL, Wang N, Zhang BB, Li M. Blockade of T-type Ca(2+) channels
inhibits human ovarian cancer cell proliferation. Cancer Invest. 2011;29:339–46.10. Valerie NC, Dziegielewska B, Hosing AS, Augustin E, Gray LS, Brautigan DL,
et al. Inhibition of T-type calcium channels disrupts Akt signaling and promotes
apoptosis in glioblastoma cells. Biochem Pharmacol. 2013;85:888–97.
11. Zhang Y, Zhang J, Jiang D, Zhang D, Qian Z, Liu C, et al. Inhibition of T-type
Ca(2+) channels by endostatin attenuates human glioblastoma cell proliferation
and migration. Br J Pharmacol. 2012;166:1247–60.
12. Taylor JT, Huang L, Pottle JE, Liu K, Yang Y, Zeng X, et al. Selective blockade
of T-type Ca2+ channels suppresses human breast cancer cell proliferation.
Cancer Lett. 2008;267:116–24.
13. Lu F, Chen H, Zhou C, Liu S, Guo M, Chen P, et al. T-type Ca2+ channel
expression in human esophageal carcinomas: a functional role in proliferation.
Cell Calcium. 2008;43:49–58.
14. Li Y, Liu S, Lu F, Zhang T, Chen H, Wu S, et al. A role of functional T-type
Ca2+ channel in hepatocellular carcinoma cell proliferation. Oncol Rep.
2009;22:1229–35.
15. Das A, Pushparaj C, Bahí N, Sorolla A, Herreros J, Pamplona R, et al. Functional
expression of voltage-gated calcium channels in human melanoma. Pigment
Cell Melanoma Res. 2012;25:200–12.
16. Dziegielewska B, Brautigan DL, Larner JM, Dziegielewski J. T-type Ca2
+ channel inhibition induces p53 dependent cell growth arrest and
apoptosis through activation of p38-MAPK in colon cancer cells.
Mol Cancer Res. 2014;12:348–58.
17. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium
channels. Physiol Rev. 2003;83:117–61.
18. Crunelli V, Toth TI, Cope DW, Blethyn K, Hughes SW. The ‘window’ T-type
calcium current in brain dynamics of different behavioural states. J Physiol.
2005;562:121–9.
19. Carbone E, Lux HD. A low voltage-activated calcium conductance in embryonic
chick sensory neurons. Biophys J. 1984;46:413–8.
20. McCobb DP, Best PM, Beam KG. Development alters the expression of
calcium currents in chick limb motorneurons. Neuron. 1989;2:1633–43.
21. Kostyuk P, Pronchuk N, Savcehnko A, Verkhratsky A. Calcium currents in
aged rat dorsal root ganglion neurones. J Physiol. 1993;461:467–83.
22. Xu XP, Best PM. Increase in T-type calcium current in atrial myocytes from adult
rats with growth hormone-secreting tumors. Proc Natl Acad Sci U S A.
1990;87:4655–9.
23. Mishra SK, Hermsmeyer K. Selective inhibition of T-type Ca2+ channels by
Ro 40–5967. Circ Res. 1994;75:144–8.
24. Huang L, Keyser BM, Tagmose TM, Hansen JB, Taylor JT, Zhuang H, et al.
NNC 55–0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)
ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate
dihydrochloride]: a new selective inhibitor of
T-type calcium channels. J Pharmacol Exp Ther. 2004;309:193–9.
25. Roger S, Rollin J, Barascu A, Besson P, Raynal PI, Iochmann S, et al.
Voltage-gated sodium channels potentiate the invasive capacities of human
non-small-cell lung cancer cell lines. Int J Biochem Cell Biol. 2007;39:774–86.
26. Zhou B, Chen H, Wei D, Kuang Y, Zhao X, Li G, et al. A novel
miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular
carcinoma. J Exp Clin Cancer Res. 2014;33:55.
27. Huang WF, Ouyang S, Li SY, Lin YF, Ouyang H, Zhang H, et al. Effect of
quercetin on colon contractility and L-type Ca(2+) channels in colon
smooth muscle of guinea-pig. Sheng Li Xue Bao. 2009;61:567–76.
28. Kotturi MF, Carlow DA, Lee JC, Ziltener HJ, Jefferies WA. Identification
and functional characterization of voltage-dependent calcium channels
in T lymphocytes. J Biol Chem. 2003;278:46949–60.
29. Atherfold PA, Norris MS, Robinson PJ, Gelfand EW, Franklin RA. Calcium-
induced ERK activation in human T lymphocytes. Mol Immunol. 1999;36:543–9.
30. Franklin RA, Atherfold PA, McCubrey JA. Calcium-induced ERK activation in
human T lymphocytes occurs via p56 (Lck) and CaM-kinase. Mol Immunol.
2000;37:675–83.
31. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-
apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552–65.
32. Orrenius S, Nicotera P. The calcium ion and cell death. J Neural Transm
Suppl. 1994;43:1–11.
33. Berridge MJ, Bootman MD, Lipp P. Calcium–a life and death signal. Nature.
1998;395:645–8.
34. Rossier MF. T channels and steroid biosynthesis: in search of a link with
mitochondria. Cell Calcium. 2006;40:155–64.
35. Csordás G, Renken C, Várnai P, Walter L, Weaver D, Buttle KF, et al. Structural
and functional features and significance of the physical linkage between ER
and mitochondria. J Cell Biol. 2006;174:915–21.
Huang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:54 Page 15 of 1536. Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, et al.
BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for
apoptosis. Science. 2003;300:135–9.
37. Whitfield JF. Calcium signals and cancer. Crit Rev Oncog. 1992;3:55–90.
38. Taylor JT, Zeng XB, Pottle JE, Lee K, Wang AR, Yi SG, et al. Calcium signaling
and T-type calcium channels in cancer cell cycling. World J Gastroenterol.
2008;14:4984–91.
39. Latour I, Louw DF, Beedle AM, Hamid J, Sutherland GR, Zamponi GW.
Expression of T-type calcium channel splice variants in human glioma. Glia.
2004;48:112–9.
40. Panner A, Wurster RD. T-type calcium channels and tumor proliferation.
Cell Calcium. 2006;40:253–9.
41. Ohkubo T, Yamazaki J. T-type voltage-activated calcium channel Cav3.1, but
not Cav3.2, is involved in the inhibition of proliferation and apoptosis in
MCF-7 human breast cancer cells. Int J Oncol. 2012;41:267–75.
42. Kahl CR, Means AR. Regulation of cell cycle progression by calcium/
calmodulin-dependent pathways. Endocr Rev. 2003;24:719–36.
43. Panner A, Cribbs LL, Zainelli GM, Origitano TC, Singh S, Wurster RD.
Variation of T-type calcium channel protein expression affects cell division
of cultured tumor cells. Cell Calcium. 2005;37:105–19.
44. Steinhardt RA, Alderton J. Intracellular free calcium rise triggers nuclear
envelope breakdown in the sea urchin embryo. Nature. 1988;332:364–6.
45. Hsu YF, Lee TS, Lin SY, Hsu SP, Juan SH, Hsu YH, et al. Involvement of Ras/
Raf-1/ERK actions in the magnolol-induced upregulation of p21 and
cell-cycle arrest in colon cancer cells. Mol Carcinog. 2007;46:275–83.
46. Tsukamoto I, Kojo S. Effect of calcium channel blockers and trifluoperazine
on rat liver regeneration. Eur J Pharmacol. 1987;144:159–62.
47. Fan H, Villegas C, Wright JA. Ribonucleotide reductase R2 component is a
novel malignancy determinant that cooperates with activated oncogenes
to determine transformation and malignant potential. Proc Natl Acad Sci U
S A. 1996;93:14036–40.
48. Son YK, da Hong H, Li H, Kim DJ, Na SH, Park H, et al. The Ca2+ channel
inhibitor NNC 55–0396 inhibits voltage-dependent K+ channels in rabbit
coronary arterial smooth muscle cells. J Pharmacol Sci. 2014;125:312–9.
49. Rizzuto R, Pinton P, Ferrari D, Chami M, Szabadkai G, Magalhaes PJ, et al.
Calcium and apoptosis: facts and hypotheses. Oncogene. 2003;22:8619–27.
50. Eberhard M, Miyagawa K, Hermsmeyer K, Erne P. Effects of mibefradil on
intracellular Ca2+ release in cultured rat cardiac fibroblasts and human
platelets. Naunyn Schmiedebergs Arch Pharmacol. 1995;353:94–101.
51. Das A, Pushparaj C, Herreros J, Nager M, Vilella R, Portero M, et al. T-type
calcium channel blockers inhibit autophagy and promote apoptosis of
malignant melanoma cells. Pigment Cell Melanoma Res. 2013;26:874–85.
52. Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to
die. Biochem Soc Trans. 2006;34:232–7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
